Literature DB >> 23869679

Understanding the course of Peyronie's disease.

G Garaffa1, L W Trost, E C Serefoglu, D Ralph, W J G Hellstrom.   

Abstract

AIMS: To correct common misconceptions about Peyronie's disease (PD) that present obstacles to early recognition and treatment.
METHODS: The prevalence, natural disease course, psychosocial effects and treatment considerations for patients with PD were reviewed.
RESULTS: Studies over the past decade have shown that the prevalence of PD may be higher (up to 20%) than previously thought. PD can lead to emotional and relationship distress. Nearly 10% of men who present with PD are younger than 40. Both younger age and comorbid vascular disease have been associated with more severe and progressive PD. In the majority of patients, symptoms will either deteriorate or remain stable. PD is often associated with erectile dysfunction (ED). Effective, minimally invasive treatments used early in the disease course include unapproved and/or investigational intralesional injection therapy with verapamil, interferon (IFN) α-2b, or collagenase clostridium histolyticum (CCH). Surgical intervention is considered in patients with ED and/or penile deformity that impairs sexual functioning; however, preoperative discussion of appropriate expectations is important. DISCUSSION: The availability of effective minimally invasive and surgical therapies for PD suggests that active management should be considered over a 'wait-and-see' approach.
CONCLUSION: Providing early intervention and improved education/awareness of PD as a chronic and progressive disorder may result in improved physical and psychosocial outcomes for PD patients. As general practitioners are often the first contact for men with PD, they are well positioned to recognise symptoms early and promptly refer patients for further evaluation and treatment.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23869679     DOI: 10.1111/ijcp.12129

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  13 in total

Review 1.  Surgical management of Peyronie's disease.

Authors:  Uwais B Zaid; Amjad Alwaal; Xiaoyu Zhang; Tom F Lue
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

2.  The direction and severity of penile curvature does not have an impact on concomitant vasculogenic erectile dysfunction in patients with Peyronie's disease.

Authors:  E C Serefoglu; L Trost; S C Sikka; W J G Hellstrom
Journal:  Int J Impot Res       Date:  2014-07-17       Impact factor: 2.896

Review 3.  Stem-cell therapy for erectile dysfunction: a review of clinical outcomes.

Authors:  Mingyue He; Ernst R von Schwarz
Journal:  Int J Impot Res       Date:  2020-04-29       Impact factor: 2.896

Review 4.  The Natural History of Peyronie's Disease.

Authors:  Fabrizio Di Maida; Gianmartin Cito; Luca Lambertini; Francesca Valastro; Girolamo Morelli; Andrea Mari; Marco Carini; Andrea Minervini; Andrea Cocci
Journal:  World J Mens Health       Date:  2020-07-08       Impact factor: 5.400

5.  Prevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie's disease: a retrospective analysis of 309 cases.

Authors:  Gianni Paulis; Gennaro Romano; Andrea Paulis
Journal:  Res Rep Urol       Date:  2016-07-18

Review 6.  All about Peyronie's disease.

Authors:  Ahmed A Hussein; Amjad Alwaal; Tom F Lue
Journal:  Asian J Urol       Date:  2015-04-16

7.  Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application.

Authors:  Gianni Paulis; Andrea Paulis; Gennaro Romano; Davide Barletta; Andrea Fabiani
Journal:  Res Rep Urol       Date:  2017-07-20

Review 8.  Recent Pathophysiological Aspects of Peyronie's Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment-Literature Review.

Authors:  Gianni Paulis; Gennaro Romano; Luca Paulis; Davide Barletta
Journal:  Adv Urol       Date:  2017-07-04

9.  Changes in the Effects of Peyronie's Disease After Treatment With Collagenase Clostridium histolyticum: Male Patients and Their Female Partners.

Authors:  Irwin Goldstein; L Dean Knoll; Larry I Lipshultz; Ted Smith; Gregory J Kaufman; Chris G McMahon
Journal:  Sex Med       Date:  2017-04-05       Impact factor: 2.491

Review 10.  Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.

Authors:  Fuxun Zhang; Feng Qin; Jiuhong Yuan
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.